FDA Investigator J David Doleski
J David Doleski has inspections in 9 countries as of 27 Jun 2023. J David Doleski has collaborated with a combined 2996 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
14
Last Inspection Date:
27 Jun 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
Country:
Singapore,
Netherlands,
United States of America,
Israel,
Belgium,
Germany,
Canada,
United Kingdom of Great Britain and Northern Ireland,
Italy
Co-Investigator(s):
A Williams,
Alexey Khrenov, PhD,
Alla Kachko, PhD,
Ana S Cabrera,
Anastasia I Offordile,
Angela K Shen,
Anissa M Cheung,
Anita Narula, PhD,
Anita R Michael,
Ann L Demarco,
Ann Marie Montemurro,
Ann Marie Schofield,
Annemarie Bodnar,
Anthony F Lorenzo,
Arduino Frankovic,
Arie C Menachem,
Audrey Thereset Uy,
Brentley S Collins,
Brian S Keefer,
Burnell M Henry,
Byungja E Marciante,
Cassandra Overking,
CDR Donald Ertel,
CDR Jeremy L Wally, PhD,
Chad R Burger,
Chao Ming Tsai,
Christian D Lynch (CDL),
Christina D Lynch,
Christina J Sauder, PhD,
Christopher J Adams,
Craig D Zagata,
Creighton T Tuzon,
Cynthia Jim, CSO,
Darla J Christopher,
Dave Hafner,
David Doleski,
David Doteski,
David J Hafner,
David S Cho, PhD,
Dawn L Wydner,
Debra J Bennett,
Debra L Pagano,
Destry M Sillivan,
Donald C Obenhuber, PhD,
Eileen A Liu,
Ellen Huang,
Erika V Butler,
Ewa Marszal, PhD,
Felice D'agnillo, PhD,
Gene D Arcy,
Hala L Selby,
Haruhiko Murata,
Helen B Ricalde,
Hyesuk Kong,
Jacqueline Mdiaz Albertini,
James L Kenney, DSc,
James M Mason,
James M Simpson,
James R Evans,
James T Mccoy,
Jean M Kelahan,
Jennifer Macmillan,
Joan A Loreng,
Joan Adamo,
Joanne M Hajoway,
Joanne Pryzbylik,
John D Finkbohner, PhD,
John F Cipollo,
John M Mcinnis,
Jon Park,
Joseph George,
Jude C Dikes,
Julianne C Mccullough,
Julie D Bringger,
Junho Pak,
Karyn M Campbell,
Kathleen B Mihalik,
Kathryn Carbone, MD,
Kelly I Anderson,
Kelly N Kerr,
Kenneth M Gordon,
Kevin P Foley,
Kimberly M Bigler,
Kristen D Evans,
Laurel A Beer,
Laurie P Norwood,
LCDR Debra Emerson,
LCDR Margaret E Digennaro,
Lewis K Antwi,
Linda Thai,
Lisa Feela,
Lisa M Bellows,
Lixin Xu, MD, PhD,
Lori S Lawless,
LT John M Mastalski,
Madushini Dharmasena, PhD,
Marc S Neubauer,
Marian E Major, PhD,
Marion Michaelis,
Mariza M Jafary,
Mark A Elengold,
Mark I Schwartz,
Martha O'lone,
Martha T Olone,
Mary T Carden,
Meihong Liu,
Michael C Kennedy, PhD,
Michael Curbag,
Michael Gurbarg,
Mihaly S Ligmond,
Nawab A Siddiqui,
Nicholas Obiri, PhD,
Nicole K Trudel,
Olga Simakova,
Omatunde O Osunsamni,
Omotunde O Osunsanmi,
Omotunder O Osunsanmi,
Pankaj H Amin,
Patricia A Morrow,
Paul A Bonneau,
Paula A Trost,
Prabhu P Raju,
Prajakta A Varadkar,
Priscilla M Pastrana,
Qiao Y Bobo,
Ramon E Martinez,
Randa Melhem, PhD,
Rebecca K Olin,
Regina Gibson Melton,
Richard D Manney,
Robert B Shibuya, MD,
Robert D Tollefsen,
Robert W Jennings,
Robin Levis, PhD,
Rona A Leblanc,
Ronald T Nowalk,
Rose Ashley,
Rose M Ashley,
Santos E Camara,
Sarah Forney,
Sarah Johnson, PhD,
Scott E Norris,
Scott T Ballard,
Sean R Bryd,
Seneca D Toms,
Sheila Dreher Lesnick,
Sheryl A Kochman,
Shuang Tang,
Sidney B Priesmeyer,
Simone E Pitts,
Stephanie Mangigian, MS/OSH, RN,
Stephen D Brown,
Steven A Rubin,
Steven P Donald,
Susan F Laska, MS,
Susan M Jackson,
Susan Yu,
Tammy L Chavis,
Teresita C Mercado,
Thomas E Friel,
Tim S Roecklein,
Tina S Roecklein,
Troy C Quander,
Viviana Matta,
Vlada Matusovsky,
Wei Wang, PhD,
Xiao Wang,
Yanming An, PhD,
Yiping Jia,
Zhihao Qiu (Peter), PhD
J David Doleski's Documents
Publish Date | Document Type | Title |
---|---|---|
November, 2007 | FDA 483 | CAF-DAF scrl - Form 483, 2007-12-07 |
November, 2007 | EIR | CAF-DAF scrl - EIR, 2008-10-10 |
February, 2010 | FDA 483 | Kamada - Production Plant - Form 483, 2010-02-11 |
December, 2007 | FDA 483 | Prothya Biosolutions Netherlands B.V. - Form 483, 2007-12-07 |
August, 2012 | FDA 483 | Lonza Biologics Tuas Pte Ltd. - Form 483, 2012-08-03 |
November, 2007 | FDA 483 Response | CAF-DAF scrl - Form 483R, 2007-11-29 |
December, 2007 | EIR | Prothya Biosolutions Netherlands B.V. - EIR, 2007-12-07 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more